Key Events This Week
Apr 20: Stock opens week at Rs.1,232.25, down 0.25% amid flat Sensex
Apr 21: Continued decline to Rs.1,220.75 despite Sensex rallying 0.77%
Apr 22: Stock dips further to Rs.1,217.00 as Sensex slips 0.23%
Apr 23: Sharp rebound with 9.54% surge to Rs.1,333.05 on technical upgrade
Apr 24: Slight pullback to Rs.1,315.85 as MarketsMOJO upgrades rating to Buy
Monday, 20 April 2026: Modest Decline Amid Flat Market
Dr Reddys Laboratories began the week at Rs.1,232.25, down 0.25% from the previous Friday’s close of Rs.1,235.40. This slight dip occurred despite the Sensex remaining largely unchanged, closing at 35,814.68 with a marginal 0.02% loss. The stock’s volume was moderate at 138,715 shares, reflecting cautious investor sentiment amid a quiet market start.
Tuesday, 21 April 2026: Stock Underperforms as Sensex Advances
The downward trend continued on Tuesday with Dr Reddys slipping 0.93% to Rs.1,220.75, even as the Sensex rallied 0.77% to 36,091.30. The divergence highlighted relative weakness in the stock, compounded by a sharp drop in volume to 27,353 shares. This underperformance suggested profit-taking or sector-specific pressures despite broader market optimism.
Wednesday, 22 April 2026: Further Decline Amid Market Weakness
On Wednesday, the stock edged down another 0.31% to Rs.1,217.00, tracking the Sensex’s 0.23% decline to 36,009.59. Volume increased to 49,790 shares, indicating some renewed trading interest. The stock’s continued slide over three consecutive sessions set the stage for a technical reversal, as investors awaited fresh catalysts.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Thursday, 23 April 2026: Technical Momentum Sparks 9.54% Surge
Thursday marked a dramatic turnaround as Dr Reddys Laboratories surged 9.54% to close at Rs.1,333.05, with intraday highs reaching Rs.1,357.00. This sharp rebound followed a technical upgrade by MarketsMOJO, which shifted the stock’s momentum rating from mildly bullish to outright bullish. The volume exploded to 996,659 shares, reflecting strong buying interest and renewed investor confidence.
The stock outperformed the Sensex, which fell 0.78% to 35,729.71, by a wide margin. Key technical indicators such as the Moving Average Convergence Divergence (MACD) turned bullish on the weekly chart, while Bollinger Bands signalled upward price pressure. Despite some caution from monthly indicators, the short-term trend was decisively positive.
Fundamentally, the company’s low debt-to-equity ratio of 0.01 and healthy Return on Equity of 15.78% supported the positive sentiment. Although recent quarterly results showed a decline in profit before tax by 18.3%, the market appeared to focus on the longer-term growth trajectory and improving technical signals.
Friday, 24 April 2026: Slight Pullback Following Upgrade to Buy
On Friday, the stock retreated modestly by 1.29% to Rs.1,315.85 on volume of 297,781 shares. This followed the official upgrade by MarketsMOJO from a 'Hold' to a 'Buy' rating, reflecting confidence in the company’s fundamentals and technical outlook. The Sensex declined 1.06% to 35,349.66, continuing the broader market weakness.
The upgrade was underpinned by strong long-term fundamentals, including a compound annual growth rate of 13.12% in net sales and 18.90% in operating profit. Valuation metrics such as a Price to Book Value ratio of 3.1 and institutional ownership of 63.64% further supported the positive outlook. However, caution remains due to recent quarterly earnings softness and some mildly bearish monthly technical indicators.
Get the full story on Dr Reddys Laboratories Ltd! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this large-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Weekly Price Performance: Dr Reddys vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-20 | Rs.1,232.25 | -0.25% | 35,814.68 | -0.02% |
| 2026-04-21 | Rs.1,220.75 | -0.93% | 36,091.30 | +0.77% |
| 2026-04-22 | Rs.1,217.00 | -0.31% | 36,009.59 | -0.23% |
| 2026-04-23 | Rs.1,333.05 | +9.54% | 35,729.71 | -0.78% |
| 2026-04-24 | Rs.1,315.85 | -1.29% | 35,349.66 | -1.06% |
Key Takeaways
Positive Signals: The stock’s 6.51% weekly gain amid a 1.31% Sensex decline highlights strong relative performance. The technical momentum shift, evidenced by bullish MACD and moving averages, underpinned the sharp rebound on 23 April. The MarketsMOJO upgrade to a Buy rating reflects improved fundamentals, including low leverage, healthy ROE, and solid long-term sales and profit growth.
Cautionary Notes: Recent quarterly results showed an 18.3% decline in profit before tax and a 16.2% drop in profit after tax, signalling short-term earnings pressure. Some monthly technical indicators remain mildly bearish, suggesting potential consolidation or correction risks. The PEG ratio of 5.5 indicates that earnings growth expectations are priced in, limiting upside if growth disappoints.
Conclusion
Dr Reddys Laboratories Ltd demonstrated resilience and renewed strength during the week, with a notable technical momentum shift driving a significant price rebound. The upgrade to a Buy rating by MarketsMOJO, supported by robust fundamentals and attractive valuation metrics, adds credibility to the stock’s near-term outlook. While recent earnings softness and some cautionary technical signals advise prudence, the stock’s outperformance relative to the Sensex and sector peers underscores its appeal as a large-cap pharmaceutical leader navigating a complex market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
